Optimizing the Management of High-Risk, Localized Prostate Cancer
Sundi Debasish, 정병창, 이승배, Han Mi-Sop,
소속 상세정보
( Sundi Debasish )
Johns Hopkins Medical Institutions
정병창 ( Jeong Byong-Chang )
Sungkyunkwan University School of Medicine Department of Urology
이승배 ( Lee Seung-Bae )
Seoul National University Boramae Medical Center Department of Urology
( Han Mi-Sop )
Johns Hopkins Medical Institutions
KMID : 0358320120530120815
Abstract
Prostate cancer has a high prevalence and a rising incidence in many parts of the world. Although many screen-detected prostate cancers may be indolent, prostate cancer remains a major contributor to mortality in men. Therefore, the appropriate diagnosis and treatment of localized prostate cancer with lethal potential are of great importance. High-risk, localized prostate cancer has multiple definitions. Treatment options that should be individualized to each patient include observation, radical prostatectomy, external beam radiotherapy, brachytherapy, androgen deprivation, and combined modality treatment. Specific outcomes of radical prostatectomy and combined modality treatment for high-risk prostate cancer are reviewed. The rationale for extended pelvic lymphadenectomy at the time of surgery is discussed, as is the role for surgery in the setting of node-positive, high-risk disease. There is not yet a biomarker that accurately identifies lethal prostate cancer, but rigorous clinical studies have identified methods of optimizing oncologic outcomes in high-risk men.
키워드
Prostate-specific antigen; Prostatectomy; Prostatic neoplasms; Radiotherapy
원문 및 링크아웃 정보
등재저널 정보